Location History:
- Baroda, IN (2012 - 2019)
- Vadodara, IN (2022)
Company Filing History:
Years Active: 2012-2022
Title: Innovations by Gaurav Sanjivkumar Sheth: A Pioneer in Malic Enzyme Inhibitors
Introduction: Gaurav Sanjivkumar Sheth, based in Baroda, India, has made significant contributions to the field of pharmaceuticals with a total of five patents to his name. His work primarily focuses on developing novel compounds that serve as malic enzyme inhibitors, aiming to provide therapeutic solutions for various disorders, particularly cancers.
Latest Patents: Among his latest patents, Gaurav has developed compounds that are beneficial as malic enzyme (ME) inhibitors. These innovative compounds are aimed at treating disorders mediated by malic enzyme, such as pancreatic ductal adenocarcinoma (PDAC). The structure of these compounds is defined according to specific formulas, including various stereoisomers and analogs. Additionally, he has patented crystalline forms of S-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl] 6-α,9-α-difluoro-17-α-(furan-2-yl)carbonyloxy-11-β-hydroxy-16-α-methyl-3-oxoandrosta-1,4-diene-17-β-carbothioate, which acts as an anti-inflammatory and anti-allergic glucocorticoid compound.
Career Highlights: Gaurav Sheth's innovative work is primarily conducted at Sun Pharma Advanced Research Company Limited, where he aims to bridge the gap between research and effective therapeutic solutions. His persistent endeavor in the pharmaceutical industry demonstrates his commitment to enhancing health outcomes through innovative medication.
Collaborations: Throughout his career, Gaurav has worked alongside esteemed colleagues, including Jiten Ranchhodbhai Patel and Gopalkumar Chimanlal Patel. Their collaborative efforts contribute to the advancement of research and development in their field, fostering an environment rich in innovation.
Conclusion: Gaurav Sanjivkumar Sheth is a notable inventor dedicated to the development of novel pharmaceutical compounds, particularly in the area of malic enzyme inhibition. His ongoing work at Sun Pharma Advanced Research Company Limited and his partnerships in research signify a promising future for therapeutic innovations aimed at combating critical health issues.